In continuation of our intimation letter dated May 15, 2018 on the above mentioned subject, we would like to inform you that Biocon Limited, the promoter of the Company, on May 16, 2018, has sold 3,765,574 equity shares held in Syngene International Limited constituting 1.88% of Paid-up share capital through open market sale in accordance with SEBI's circular no. SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018.
Consequent to the aforementioned open market sale, the Company has complied with the minimum public shareholding requirements as mandated under rules 19(2)(b) and 19A of the Securities Contracts (Regulation) Rules, 1957 ('the SCRR') read with regulation 38 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.